This technology is a non-invasive urine test based on the detection of RAD9 methylation that is sensitive and accurate in detecting aggressive prostate and related cancers.
Prostate cancer is the third leading cause of cancer-related death in men. It is currently screened either by a rectal examination or prostate-specific antigen (PSA) blood test, which measures the amount of PSA in the blood. However, rectal examinations are highly invasive, and the PSA test has low sensitivity and accuracy for particularly aggressive forms of the disease. There is a need for a more sensitive, noninvasive assay to diagnose and stage aggressive forms of prostate cancer.
This assay is a noninvasive diagnostic and prognostic urine test for prostate cancer that measures levels of DNA methylation in the RAD9 gene. High RAD9 methylation and subsequent overexpression have been shown to drive prostate cancer progression. This assay can detect differences in methylation levels 10.1-fold between cancer cells and normal prostate cells. This urine test may be a more sensitive diagnostic test for aggressive prostate cancers and could also complement serum PSA blood tests to further increase the accuracy of prostate cancer diagnosis and prognosis.
This assay has been validated using human cancer and normal cell lines.
Patent Pending(WO/2023/196874)
IR CU22152
Licensing Contact: Kristin Neuman
